First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Toshio Shimizu(Kansai Medical University), Noboru Yamamoto(Tokyo National Hospital), Kan Yonemori(National Cancer Centre Japan), Takafumi Koyama(Tokyo National Hospital), Takuma Miura(Koei Chemical (Japan)), Keiji Furuuchi(Penn Presbyterian Medical Center), Yutaka Fujiwara(Kobe University), Hiroki Ikezawa(Koei Chemical (Japan)), Maiko Nomoto(Koei Chemical (Japan)), Kenji Tamura, Jun Sato(National Cancer Centre Japan), Ryo Nakajima(Eisai (United States)), Akihiko Shimomura(Tokyo National Hospital)
Clinical Cancer Research
April 29, 2021
10.1158/1078-0432.ccr-20-4740
Cited by 97

Related Papers

E-CELL: software environment for whole-cell simulation.
|Bioinformatics|1999|765
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401